




RealRate

PHARMACEUTICAL 2018

Avadel Pharmaceuticals PLC
Rank 182 of 332



The relative strengths and weaknesses of Avadel Pharmaceuticals PLC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Avadel Pharmaceuticals PLC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 90% points. The greatest weakness of Avadel Pharmaceuticals PLC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 73% points.

The company's Economic Capital Ratio, given in the ranking table, is 247%, being 5.2% points below the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	123,975
Cost of Goods Sold	16,301
Intangible Assets	110,780
Liabilities, Current	86,539
Liabilities, Non-Current	7,240
Other Assets	15,521
Other Compr. Net Income	299
Other Expenses	602
Other Liabilities	73,918
Other Net Income	4,207
Other Revenues	173,245
Property and Equipment	3,001
Research and Development	33,418
Selling, General and Administrative Expense	58,860

Output Variable	Value in 1000 USD
Assets	253,277
Liabilities	167,697
Expenses	109,181
Revenues	173,245
Stockholders Equity	85,580
Net Income	68,271
Comprehensive Net Income	68,420
BaseVar	353,953
ECR before Limited Liability	121%
Economic Capital Ratio	247%